Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Wednesday

Cognition Therapeutics (NASDAQ:CGTX) is anticipated to release its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect Cognition Therapeutics to post earnings of ($0.06) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 26, 2026 at 8:30 AM ET.

Cognition Therapeutics Stock Down 2.7%

Shares of CGTX stock opened at $1.10 on Wednesday. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83. The firm has a market cap of $97.10 million, a PE ratio of -2.29 and a beta of 1.25. The stock has a 50 day moving average of $1.16 and a 200-day moving average of $1.46.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CGTX. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Cognition Therapeutics in a research report on Thursday, December 4th. upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $3.33.

Hedge Funds Weigh In On Cognition Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CGTX. Tocqueville Asset Management L.P. lifted its holdings in Cognition Therapeutics by 18.5% during the 4th quarter. Tocqueville Asset Management L.P. now owns 192,500 shares of the company’s stock worth $260,000 after buying an additional 30,000 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Cognition Therapeutics by 35.9% in the 4th quarter. Renaissance Technologies LLC now owns 969,513 shares of the company’s stock valued at $1,309,000 after buying an additional 256,013 shares during the period. Geode Capital Management LLC raised its position in shares of Cognition Therapeutics by 22.6% during the fourth quarter. Geode Capital Management LLC now owns 873,954 shares of the company’s stock worth $1,180,000 after acquiring an additional 161,227 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Cognition Therapeutics during the third quarter valued at $138,000. Finally, Millennium Management LLC bought a new position in Cognition Therapeutics in the third quarter valued at about $757,000. 43.35% of the stock is currently owned by institutional investors and hedge funds.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.